Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy
Sponsor: PD Dr. med. Thorsten Mikoteit
Summary
In this study at the Solothurn Psychiatric Clinic, the investigators compare the effectiveness and tolerability of antidepressant pharmacotherapy in three groups. In the intervention group, the physician selects and doses the medication for depression based on a pharmacogenetic examination conducted by a clinical pharmacist. In the standard group, the treating physician selects and doses the antidepressant drug without the support of genetic testing, in accordance with current standard practice. If after the first week of hopsitalization no adjustment to a new antidepressant is necessary, the investigators will monitor the progress of these patients until they leave the clinic in an observational arm. The drugs used are all approved in Switzerland for the treatment of depression. Classification into the intervention or standard group is made randomly after the first week of hospitalisation, if the treating physician deems it necessary to change or readjust the antidepressant pharmacotherapy. The probability of allocation to one of the two study groups is 50%. All study participants will be hospitalized for at least five weeks and monitored until they leave the clinic. In total, it is planned to include and examine 95 patients each into the intervention and standard group.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
190
Start Date
2020-09-15
Completion Date
2025-12-31
Last Updated
2025-01-20
Healthy Volunteers
No
Conditions
Interventions
Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing
The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing. This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist.
Standard care antidepressant selection and dosing
Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
Locations (4)
Privatklinik Wyss
Münchenbuchsee, Canton of Bern, Switzerland
Psychiatrische Dienste Solothurn
Solothurn, Canton of Solothurn, Switzerland
Luzerner Psychiatrie AG
Sankt Urban, Switzerland
Psychiatrische Universitätsklinik Zürich
Zurich, Switzerland